Matza, Louis S. http://orcid.org/0000-0001-6374-5948
Howell, Timothy A.
Fung, Eric T.
Janes, Sam M.
Seiden, Michael
Hackshaw, Allan
Nadauld, Lincoln
Karn, Hayley
Chung, Karen C.
Funding for this research was provided by:
GRAIL, LLC (EVA-26058)
Article History
Accepted: 14 September 2023
First Online: 8 January 2024
Declarations
:
: Data will be shared upon reasonable request.
: The study protocol was approved by an institutional review board (Ethical and Independent Review Services; Study 21017-01).
: Informed consent was obtained prior to each interview.
: Informed consent included a statement regarding publication of de-identified data in journals.
: This study was funded by GRAIL, LLC, a subsidiary of Illumina Inc. currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2021.
: LM, TH, and HK are employed by Evidera, a company that received funding from GRAIL for time spent conducting this research. KC and ETF are employees of GRAIL, LLC, a subsidiary of Illumina, Inc., with equity in Illumina, Inc. MS is a paid consultant to GRAIL. AH is co-investigator for an academic study (SUMMIT) sponsored by UCL, which is funded by GRAIL, has received one honorarium for an advisory board meeting for GRAIL and an honorarium from Evidera Inc (for this current project), and previously owned shares in Illumina. LN has stock options in Culmination Bio. SJ has received fees for advisory board membership in the last three years from Astra-Zeneca, Bard1 Lifescience, and Johnson and Johnson. He has received grant income from Owlstone and GRAIL Inc. He is an unpaid member of a GRAIL advisory board. He has received lecture fees for academic meetings from Cheisi and Astra Zeneca. His wife works for Astra Zeneca.
: All authors contributed to the study conception and design. Material preparation, data collection, and analysis were directed by LM and TH. The first draft of the manuscript was written by LM and TH. The other authors provided edits and comments on the first draft. All authors read and approved the final manuscript.